CoChat

Regulation of CD4+NKG2D+ Th1 Cells in Patients with Metastatic Melanoma Treated with Sorafenib: Role of IL-15Rα and NKG2D Triggering

Open access
Romero, Ana I., Chaput, Nathalie, Poirier-Colame, Vichnou, Rusakiewicz, Sylvie, Jacquelot, Nicolas, Chaba, Kariman, Mortier, Erwan, Jacques, Yannick, Caillat-Zucman, Sophie, Flament, Caroline, Caignard, Anne, Messaoudene, Meriem, Aupérin, Anne, Vielh, Philippe, Dessen, Philippe, Porta, Camillo, Mateus, Christine, Ayyoub, Maha, Valmori, Danila, Eggermont, Alexander, Robert, Caroline, Zitvogel, Laurence · 2014 · Cancer Research
Cited by 42

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Beyond cancer-cell intrinsic factors, the immune status of the host has a prognostic impact on patients with cancer and influences the effects of conventional chemotherapies. Metastatic melanoma is intrinsically immunogenic, thereby facilitating the search for immune biomarkers of clinical responses to cytotoxic agents. Here, we show that a multi-tyrosine kinase inhibitor, sorafenib, upregulates interleukin (IL)-15Rα in vitro and in vivo in patients with melanoma, and in conjunction with natural killer (NK) group 2D (NKG2D) ligands, contributes to the Th1 polarization and accumulation of peripheral CD4+NKG2D+ T cells. Hence, the increase of blood CD4+NKG2D+ T cells after two cycles of sorafenib (combined with temozolomide) was associated with prolonged survival in a prospective phase I/II trial enrolling 63 patients with metastatic melanoma who did not receive vemurafenib nor immune checkpoint–blocking antibodies. In contrast, in metastatic melanoma patients treated with classical treatment modalities, this CD4+NKG2D+ subset failed to correlate with prognosis. These findings indicate that sorafenib may be used as an “adjuvant” molecule capable of inducing or restoring IL-15Rα/IL-15 in tumors expressing MHC class I–related chain A/B (MICA/B) and on circulating monocytes of responding patients, hereby contributing to the bioactivity of NKG2D+ Th1 cells. Cancer Res; 74(1); 68–80. ©2013 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-13-1186

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 42

Metadata

Authors
Romero, A. I., Chaput, N., Poirier-Colame, V., Rusakiewicz, S., Jacquelot, N., Chaba, K., Mortier, E., Jacques, Y., Caillat-Zucman, S., Flament, C., Caignard, A., Messaoudene, M., Aupérin, A., Vielh, P., Dessen, P., Porta, C., Mateus, C., Ayyoub, M., Valmori, D., Eggermont, A., Robert, C., & Zitvogel, L.
Venue
Cancer Research
Published
2014-01-01
Volume
74
Issue
1
Pages
68-80
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2163589263
Cited by
42
References
4
FWCI
1.73
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Regulation of CD4+NKG2D+ Th1 Cells in Patients with Metastatic Melanoma Treated with Sorafenib: Role of IL-15Rα and NKG2D Triggering. https://app.cochat.ai/papers/10.1158/0008-5472.can-13-1186
The paper
Romero, A. I., Chaput, N., Poirier-Colame, V., Rusakiewicz, S., Jacquelot, N., Chaba, K., Mortier, E., Jacques, Y., Caillat-Zucman, S., Flament, C., Caignard, A., Messaoudene, M., Aupérin, A., Vielh, P., Dessen, P., Porta, C., Mateus, C., Ayyoub, M., Valmori, D., . . . Zitvogel, L. (2014). Regulation of CD4+NKG2D+ Th1 Cells in Patients with Metastatic Melanoma Treated with Sorafenib: Role of IL-15Rα and NKG2D Triggering. Cancer Research. https://doi.org/10.1158/0008-5472.can-13-1186

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.